AFMD:NSD-Affimed NV (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.00

Change

+0.19 (+6.76)%

Market Cap

USD 0.42B

Volume

1.23M

Avg Analyst Target

USD 10.50 (+250.00%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AFMD Stock Forecast & Price:
Based on the Affimed NV stock forecasts from 3 analysts, the average analyst target price for Affimed NV is USD 10.50 over the next 12 months. Affimed NV’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Affimed NV is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Affimed NV’s stock price was USD 3.00. Affimed NV’s stock price has changed by +7.91% over the past week, -3.23% over the past month and -58.79% over the last year.

About Affimed NV (AFMD:NSD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphom ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.66 (+0.58%)

USD73.48B 29.71 20.69
REGN Regeneron Pharmaceuticals Inc

+1.16 (+0.19%)

USD65.40B 8.39 6.44
MRNA Moderna Inc

+5.59 (+3.73%)

USD59.64B 4.20 3.05
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+3.53 (+2.24%)

USD38.28B 2.86 1.54
SGEN Seagen Inc

-3.34 (-1.85%)

USD33.15B 55.02 -51.02
RPRX Royalty Pharma Plc

+0.41 (+0.96%)

USD28.81B 29.89 16.23
GMAB Genmab AS

+0.51 (+1.53%)

USD21.88B 64.29 5.76
ARGX argenx NV ADR

+4.98 (+1.32%)

USD20.88B N/A -31.64
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AFMD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.65% 46% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.65% 46% F 29% F
Trailing 12 Months  
Capital Gain -57.57% 57% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.57% 57% F 30% F
Trailing 5 Years  
Capital Gain 30.43% 76% C 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.43% 75% C 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 51.94% 82% B- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.94% 82% B- 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 96.30% 26% F 14% F
Risk Adjusted Return 53.94% 91% A- 83% B
Market Capitalization 0.42B 71% C- 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.42 29% F 25% F
Price / Cash Flow Ratio -4.85 67% D+ 71% C-
EV/EBITDA -3.57 76% C 77% C+
Management Effectiveness  
Return on Equity -52.82% 54% F 22% F
Return on Invested Capital -56.69% 48% F 18% F
Return on Assets -20.74% 63% D 20% F
Debt to Equity Ratio 12.55% 62% D- 70% C-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.27 66% D 50% F
Short Percent 2.75% 65% D 54% F
Beta 2.49 7% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.